about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerTaxanes in the elderly patient with metastatic breast cancerImmunosuppressive and anti-inflammatory properties of engineered nanomaterialsUltrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenograftsThe Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic CancersExternally modulated theranostic nanoparticlesDevelopment and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel.Vascular-targeted photodynamic therapy (VTP) of a canine-transmissible venereal tumour in a murine model with Pd-bacteriopheophorbide (WST09).An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties.Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.Taxane pathway.Novel formulations of taxanes: a review. Old wine in a new bottle?Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer.Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption.Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.Disposition kinetics of taxanes in peritoneal disseminationEvaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).Development and qualification of an LC-MS/MS method for investigating the biological implications of micelle entrapped paclitaxel in cell culture and rats.Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs.Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.Drug interactions in cancer therapy.Preclinical formulations for discovery and toxicology: physicochemical challenges.A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokineticsDegradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy.First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Nanoformulation of natural products for prevention and therapy of prostate cancer.Larotaxel: broadening the road with new taxanes.Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
P2860
Q24657308-37EDA82D-2F21-4F24-91FF-96DC9F45544BQ26785458-747440A4-C751-42FF-A6D2-EA8A5A154FD6Q27005267-3BE52AA1-C13F-4E22-8517-79E2F548373CQ28487464-A174FC98-4545-40A2-9ECC-B2173A201F92Q28551531-98BE9F73-F2C3-48C7-AEA0-4002B5A4E59DQ30438597-5179934A-159D-4220-B008-4BB3AB0D19FEQ30618973-8FDB1668-0B80-4F86-8814-E4895628221BQ33503377-B463E293-C740-4DDB-AEC8-C284E415B201Q33563915-8F7C3510-F687-41F2-9AAC-B9CF3BF2897CQ33795052-0B15E70A-948B-4DD4-AA48-0FD13162C04FQ33851448-FE167E4E-C7CE-4D08-AD0A-74C85B340BC5Q33916040-48FF54CA-D82F-49F6-8864-3652D816875FQ33949865-B4EE3CB9-736D-4493-9D11-FEA364B64F14Q34079286-00619FB7-BDCC-41DA-BB9F-72B3860B10B6Q34390370-9F2030B5-6223-4838-B711-A49C7F807F3CQ34563540-4B9ACAF7-4DF6-4189-A7F2-4C5456FE20F5Q34982543-58418D16-E99D-4932-87EC-41B7249AECC8Q35045144-BB6140D4-DFE2-4C36-9939-88450ADF6FDCQ35147276-53032E44-2E2A-43D0-A903-0B9FA2F7E4A5Q35166688-154FD720-C9F5-465B-8351-B13BEF738E5EQ35994258-D47A01EF-9118-4789-91D8-33CC7D75798CQ36071814-7C4F4916-38EB-4F89-ADCD-78A00E2A5FE6Q36282159-B7722001-F9B9-4430-9546-177234E6E02DQ36349701-0FC6154B-C781-4C6A-85DC-1E09B94DE5F1Q36429614-9309F592-2874-467A-B829-5DC991BC601FQ36516421-6BD48AB8-45AD-477D-B55F-DB274588BECAQ36609758-75963153-D83E-45AB-B745-4CBFDD78D151Q36611637-44DE8567-C59D-410D-A619-10C6A839740CQ36726598-84FFCDA3-DE8F-4B12-A28D-3D7683EDCE14Q36879127-1A91BFC1-DEB9-4E3C-807B-5F693C8049AFQ36988072-69E13F39-5D76-4FA0-9E46-3B1DEE97010CQ37262298-DF38AA56-A90C-46BA-97BE-3DE0B73B5988Q37402532-CE63BBAC-E6E7-428B-93C8-8BF3FF1D6495Q37419857-2B46E426-2458-4AB0-B54A-F0A90B1AA4E1Q37473193-BEA02263-019B-4AC7-BF01-86E97B399637Q37551909-21D16ED9-7E64-4203-BA46-26644AB1250CQ37623841-B40E067D-D441-45C2-97B3-FDD9173F59B0Q37682906-A77DBDAA-07BB-4149-8288-22C33575433FQ37798555-E9867E12-C8A6-427D-A755-CAC1D32043C1Q37815479-0743161E-601D-4BAD-B0FF-F6D305285FF6
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Role of formulation vehicles in taxane pharmacology.
@ast
Role of formulation vehicles in taxane pharmacology.
@en
type
label
Role of formulation vehicles in taxane pharmacology.
@ast
Role of formulation vehicles in taxane pharmacology.
@en
prefLabel
Role of formulation vehicles in taxane pharmacology.
@ast
Role of formulation vehicles in taxane pharmacology.
@en
P2093
P356
P1476
Role of formulation vehicles in taxane pharmacology.
@en
P2093
Sparreboom A
van Zuylen L
P2888
P304
P356
10.1023/A:1010618632738
P577
2001-05-01T00:00:00Z
P6179
1003425850